ECM
ACAD icon

ETrade Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

ETrade Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,509
Closed -$260K – 736
2018
Q3 		$260K Buy
12,509
+623
+5% +$9.8K 0.01% 733
2018
Q2 		$181K Buy
+11,886
New +$212K 0.01% 763

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

ETrade Capital Management's ACAD Position: Q4 2018 in Review

ETrade Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2018, closing a stake of 12,509 shares — an estimated $260K sold.

ETrade Capital Management first reported a position in ACAD in Q2 2018 and held it in 2 quarters. The position peaked at $260K in Q3 2018. 186 funds tracked by Wall St. Rank hold ACAD as of Q4 2018.

  • ETrade Capital Management reported no remaining Acadia Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • ETrade Capital Management sold 12,509 Acadia Pharmaceuticals shares in Q4 2018, an estimated $260K.
  • ETrade Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • ETrade Capital Management's Acadia Pharmaceuticals position peaked at $260K in Q3 2018.
  • 186 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2018.

Based on ETrade Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.